| GEFTINAT 250mg: |
Each tablet contains Gefitinib 250mg. |
|
| Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells. |
|
| |
| Indications: |
| GEFTINAT (Gefitinib) is indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer. |
|
| |
| Dosage & Usage: |
| The recommended daily dose of GEFTINIB in one 250mg tablet with or without food. Higher doses do not give a better response and may cause increased toxicity. It is advisable to consult your doctor to prescribe the dosage that suits your condition. |
|
| |
| Side Effects: |
| Some common side effects that may occur as a result of the usage of Geftinat tablets, include - diarrhea, rashes, itching, dry skin and acne. If side effects persist or worsen, consult your doctor immediately |
|
| |
| Note: |
| Geftinat is a prescription drug and should be used under proper medical guidance and advice. |
|
